Bioinformatic analysis of chemokine (C-C motif) ligand 21 and SPARC-like protein 1 revealing their associations with drug resistance in ovarian cancer

International Journal of Oncology

Volumn 42, Issue 4, 2013, Pages 1305-1316

  Yin, Fuqiang ^a,b   Liu, Xia ^b   Li, Danrong ^a   Wang, Qi ^b   Zhang, Wei ^b   Li, Li ^a,b  

^a Medical University   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Bioinformatic; Chemokine (C C motif) ligand 21; Drug resistance; Ovarian cancer; SPARC like protein 1

Indexed keywords

PROTEIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; SECRETED PROTEIN ACIDIC AND RICH IN CYSTEINE LIKE PROTEIN 1; UNCLASSIFIED DRUG;

ARTICLE; BIOINFORMATICS; GENE INTERACTION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

CALCIUM-BINDING PROTEINS; CHEMOKINE CCL21; COMPUTATIONAL BIOLOGY; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE ANNOTATION; OVARIAN NEOPLASMS; PROTEIN INTERACTION MAPS;

EID: 84874602501     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1819     Document Type: Article

References (109)

1. Balch C, Huang TH, Brown R and Nephew KP: The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191:1552-1572, 2004.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 58:71-96, 2008.
3. Cannistra SA: Cancer of the ovary. N Engl J Med 351:2519-2529, 2004.
4. Bast RC Jr, Hennessy B and Mills GB: The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415-428, 2009.
5. Fraser M, Bai T and Tsang BK: Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Int J Cancer 122:534-546, 2008.
6. Hagopian GS, Mills GB, Khokhar AR, Bast RC Jr and Siddik ZH: Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane) (trans-diacetato) (dichloro)-platinum (IV). Clin Cancer Res 5:655-663, 1999.
7. Zhou C, Smith JL and Liu J: Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396-2404, 2003.
8. Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK and Zhang W: Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557-1565, 2011.
9. Wu L, Wu A and Jiang K: Effect of antisense c-erbB2 on biologic behaviour and chemotherapeutic drug sensitivity in human ovarian cancer cells. Zhonghua Fu Chan Ke Za Zhi 31:169-172, 1996 (In Chinese).
10. Benoit DS, Henry SM, Shubin AD, Hoffman AS and Stayton PS: pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm 7:442-455, 2010.
11. Itamochi H: Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem 1:209-220, 2010.
12. Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. Nature 474:609-615, 2011.
13. Narod S, Moody J, Rosen B, Fan I, Risch A, Sun P and McLaughlin J: Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet: June 8, 2012 (Epub ahead of print).
14. Szabova L, Yin C, Bupp S, et al: Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer. Cancer Res 72:1-13, 2012.
15. Thangaraju M, Kaufmann SH and Couch FJ: BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem 275:33487-33496, 2000.
16. Connor JP, Felder M, Kapur A and Onujiogu N: DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1. BMC Cancer 12:176, 2012.
17. Quinn JE, James CR, Stewart GE, et al: BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 13:7413-7420, 2007.
18. Yellaboina S, Tasneem A, Zaykin DV, Raghavachari B and Jothi R: DOMINE: a comprehensive collection of known and predicted domain-domain interactions. Nucleic Acids Res 39:D730-D735, 2011.
19. Raghavachari B, Tasneem A, Przytycka TM and Jothi R: DOMINE: a database of protein domain interactions. Nucleic Acids Res 36:D656-D661, 2008.
20. Jenssen TK, Laegreid A, Komorowski J and Hovig E: A literature network of human genes for high-throughput analysis of gene expression. Nat Genet 28:21-28, 2001.
21. Mostafavi S, Ray D, Warde-Farley D, Grouios C and Morris Q: GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. Genome Biol 9(Suppl 1):S4, 2008.
22. Baitaluk M, Sedova M, Ray A and Gupta A: BiologicalNetworks: visualization and analysis tool for systems biology. Nucleic Acids Res 34:W466-W471, 2006.
23. Dweep H, Sticht C, Pandey P and Gretz N: miRWalk - database: prediction of possible miRNA binding sites by 'walking' the genes of three genomes. J Biomed Inform 44:839-847, 2011.
24. Papadopoulos GL, Alexiou P, Maragkakis M, Reczko M and Hatzigeorgiou AG: DIANA-mirPath: integrating human and mouse microRNAs in pathways. Bioinformatics 25:1991-1993, 2009.
25. Baggiolini M, Dewald B and Moser B: Human chemokines: an update. Annu Rev Immunol 15:675-705, 1997.
26. Xu Y, Liu L, Qiu X, et al: CCL21/CCR7 prevents apoptosis via the ERK pathway in human non-small cell lung cancer cells. PLoS One 7:e33262, 2012.
27. Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF and Wu CM: CCL7 and CCL21 overexpression in gastric cancer is associated with lymph node metastasis and poor prognosis. World J Gastroenterol 18:1249-1256, 2012.
28. Xu Y, Liu L, Qiu X, et al: CCL21/CCR7 promotes G2/M phase progression via the ERK pathway in human non-small cell lung cancer cells. PLoS One 6:e21119, 2011.
29. Yousefieh N, Hahto SM, Stephens AL and Ciavarra RP: Regulated expression of CCL21 in the prostate tumor microenvironment inhibits tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Microenviron 2:59-67, 2009.
30. Zhang H, Widegren E, Wang DW and Sun XF: SPARCL1: a potential molecule associated with tumor diagnosis, progression and prognosis of colorectal cancer. Tumour Biol 32:1225-1231, 2011.
31. Hambrock HO, Nitsche DP, Hansen U, Bruckner P, Paulsson M, Maurer P and Hartmann U: SC1/hevin. An extracellular calcium-modulated protein that binds collagen I. J Biol Chem 278:11351-11358, 2003.
32. Girard JP and Springer TA: Modulation of endothelial cell adhesion by hevin, an acidic protein associated with high endothelial venules. J Biol Chem 271:4511-4517, 1996.
33. Li P, Qian J, Yu G, Chen Y, Liu K, Li J and Wang J: Down-regulated SPARCL1 is associated with clinical significance in human gastric cancer. J Surg Oncol 105:31-37, 2012.
34. Yu SJ, Yu JK, Ge WT, Hu HG, Yuan Y and Zheng S: SPARCL1, Shp2, MSH2, E-cadherin, p53, ADCY-2 and MAPK are prognosis-related in colorectal cancer. World J Gastroenterol 17:2028-2036, 2011.
35. Sullivan MM and Sage EH: Hevin/SC1, a matricellular glycoprotein and potential tumor-suppressor of the SPARC/BM-40/Osteonectin family. Int J Biochem Cell Biol 36:991-996, 2004.
36. Mintz MB, Sowers R, Brown KM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65:1748-1754, 2005.
37. Song J, Wang X, Lei C, et al: Fusion of chemotactic peptide to a single-chain bi-specific antibody (scBsAb) potentiates its cytotoxicity to target tumour cells. Biotechnol Appl Biochem 45:147-154, 2006.
38. Biade S, Marinucci M, Schick J, et al: Gene expression profiling of human ovarian tumours. Br J Cancer 95:1092-1100, 2006.
39. Lu X, Zhai C, Gopalakrishnan V and Buchanan BG: Automatic annotation of protein motif function with Gene Ontology terms. BMC Bioinformatics 5:122, 2004.
40. Yang W, Chen LP, Huang R and Huang RP: Inhibition of IL-6 and IL-8 enhances chemosensitization in multidrug resistant human breast cancer cells. AACR Meeting Abstracts 2005:1199-c, 2005.
41. Duan Z, Feller AJ, Penson RT, Chabner BA and Seiden MV: Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. Clin Cancer Res 5:3445-3453, 1999.
42. Soon WW, Miller LD, Black MA, et al: Combined genomic and phenotype screening reveals secretory factor SPINK1 as an invasion and survival factor associated with patient prognosis in breast cancer. EMBO Mol Med 3:451-464, 2011.
43. Chen T, Lee TR, Liang WG, Chang WS and Lyu PC: Identification of trypsin-inhibitory site and structure determination of human SPINK2 serine proteinase inhibitor. Proteins 77:209-219, 2009.
44. Kutuzov MA, Bennett N and Andreeva AV: Protein phosphatase with EF-hand domains 2 (PPEF2) is a potent negative regulator of apoptosis signal regulating kinase-1 (ASK1). Int J Biochem Cell Biol 42:1816-1822, 2010.
45. Gibadulinova A, Tothova V, Pastorek J and Pastorekova S: Transcriptional regulation and functional implication of S100P in cancer. Amino Acids 41:885-892, 2011.
46. Zhu W, Xu H, Zhu D, et al: miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69:723-731, 2012.
47. Hong JH, Lee E, Hong J, Shin YJ and Ahn H: Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder cancer cell lines. BJU Int 90:113-117, 2002.
48. Dhar DK, Nagasue N, Yoshimura H, et al: Overexpression of P-glycoprotein in untreated AFP-producing gastric carcinoma. J Surg Oncol 60:50-54, 1995.
49. Xu Z, Wang M, Wang L, Wang Y, Zhao X, Rao Q and Wang J: Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res 33:891-897, 2009.
50. Liu Z and Chen S: ER regulates an evolutionarily conserved apoptosis pathway. Biochem Biophys Res Commun 400:34-38, 2010.
51. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406:747-752, 2000.
52. Dabholkar M, Bradshaw L, Parker RJ, Gill I, Bostick-Bruton F, Muggia FM and Reed E: Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro. Environ Health Perspect 98:53-59, 1992.
53. Jo H, Loison F, Hattori H, Silberstein LE, Yu H and Luo HR: Natural product Celastrol destabilizes tubulin heterodimer and facilitates mitotic cell death triggered by microtubule-targeting anti-cancer drugs. PLoS One 5:e10318, 2010.
54. Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 14:6735-6741, 2008.
55. Herr DR: Potential use of G protein-coupled receptor-blocking monoclonal antibodies as therapeutic agents for cancers. Int Rev Cell Mol Biol 297:45-81, 2012.
56. Ma Q, Zhang ZS, Zhang YL and Lai ZS: Relationship between multidrug resistance in human colon carcinoma LoVo/Adr cell line and intracellular calcium ion concentration. Ai Zheng 21:846-849, 2002 (In Chinese).
57. Liang X and Huang Y: Intracellular free calcium concentration and cisplatin resistance in human lung adenocarcinoma A549 cells. Biosci Rep 20:129-138, 2000.
58. Nan A, Ghandehari H, Hebert C, Siavash H, Nikitakis N, Reynolds M and Sauk JJ: Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck. J Drug Target 13:189-197, 2005.
59. Westhoff MA and Fulda S: Adhesion-mediated apoptosis resistance in cancer. Drug Resist Updat 12:127-136, 2009.
60. Benatar T, Amemiya Y, Yang W and Seth A: Insulin-like-growth factor-binding-protein 7: an antagonist to breast cancer. In: Breast Cancer - Focusing Tumor Microenvironment, Stem cells and Metastasis. Gunduz M (ed). InTech, Rijeka, pp39-68, 2011.
61. Heesch S, Schlee C, Neumann M, et al: BAALC-associated gene expression profiles define IGFBP7 as a novel molecular marker in acute leukemia. Leukemia 24:1429-1436, 2010.
62. Lane TF, Iruela-Arispe ML, Johnson RS and Sage EH: SPARC is a source of copper-binding peptides that stimulate angiogenesis. J Cell Biol 125:929-943, 1994.
63. Girard JP and Springer TA: Cloning from purified high endothelial venule cells of hevin, a close relative of the antiadhesive extracellular matrix protein SPARC. Immunity 2:113-123, 1995.
64. Socha MJ, Said N, Dai Y, et al: Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11:126-135, 2009.
65. Tai IT, Dai M, Owen DA and Chen LB: Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 115:1492-1502, 2005.
66. De Milito A and Fais S: Proton pump inhibitors may reduce tumour resistance. Expert Opin Pharmacother 6:1049-1054, 2005.
67. Logothetis CJ, Hossan EA and Smith TL: SMS 201-995 in the treatment of refractory prostatic carcinoma. Anticancer Res 14:2731-2734, 1994.
68. Matrone A, Grossi V, Chiacchiera F, et al: p38alpha is required for ovarian cancer cell metabolism and survival. Int J Gynecol Cancer 20:203-211, 2010.
69. Kapitza S, Pongratz M, Jakupec MA, et al: Heterocyclic complexes of ruthenium (III) induce apoptosis in colorectal carcinoma cells. J Cancer Res Clin Oncol 131:101-110, 2005.
70. Yokomizo A, Ono M, Nanri H, et al: Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. Cancer Res 55:4293-4296, 1995.
71. Turk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM and Szakacs G: Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res 69:8293-8301, 2009.
72. Van Jaarsveld MT, Helleman J, Berns EM and Wiemer EA: MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol 42:1282-1290, 2010.
73. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111:478-486, 2008.
74. Yang N, Kaur S, Volinia S, et al: MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 68:10307-10314, 2008.
75. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Gynecol Oncol 113:249-255, 2009.
76. Kumar S, Kumar A, Shah PP, Rai SN, Panguluri SK and Kakar SS: MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res 4:17, 2011.
77. Hilliard TS, Gaisina IN, Muehlbauer AG, Gaisin AM, Gallier F and Burdette JE: Glycogen synthase kinase 3beta inhibitors induce apoptosis in ovarian cancer cells and inhibit in-vivo tumor growth. Anticancer Drugs 22:978-985, 2011.
78. Su HY, Lai HC, Lin YW, et al: Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway. Int J Cancer 127:555-567, 2010.
79. Bellone S, Siegel ER, Cocco E, et al: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer 19:860-866, 2009.
80. Chen JY, Shen C, Yan Z, Brown DP and Wang M: A systems biology case study of ovarian cancer drug resistance. Comput Syst Bioinformatics Conf: pp389-398, 2006.
81. Shah MA and Schwartz GK: Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin Cancer Res 7:2168-2181, 2001.
82. Miller DH, Fischer AK, Chu KF, Burr R, Hillenmeyer S, Brard L and Brodsky AS: T0901317 inhibits cisplatin-induced apoptosis in ovarian cancer cells [corrected]. Int J Gynecol Cancer 21:1350-1356, 2011.
83. Trinh XB, van Dam PA, Dirix LY, Vermeulen PB and Tjalma WA: The rationale for mTOR inhibition in epithelial ovarian cancer. Expert Opin Investig Drugs 18:1885-1891, 2009.
84. Li J, Feng Q, Kim JM, et al: Human ovarian cancer and cisplatin resistance: possible role of inhibitor of apoptosis proteins. Endocrinology 142:370-380, 2001.
85. Luo T, Yu J, Nguyen J, et al: Electron transfer-based combination therapy of cisplatin with tetramethyl-p-phenylenediamine for ovarian, cervical, and lung cancers. Proc Natl Acad Sci USA 109:10175-10180, 2012.
86. Nessa MU, Beale P, Chan C, Yu JQ and Huq F: Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res 32:53-59, 2012.
87. Kumaran GC, Jayson GC and Clamp AR: Antiangiogenic drugs in ovarian cancer. Br J Cancer 100:1-7, 2009.
88. Zhang Y, Cheng Y, Ren X, et al: NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 31:1055-1064, 2012.
89. Buys TP, Chari R, Lee EH, et al: Genetic changes in the evolution of multidrug resistance for cultured human ovarian cancer cells. Genes Chromosomes Cancer 46:1069-1079, 2007.
90. Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P and Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol 117:198-201, 2010.
91. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H and Katano M: Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Anticancer Res 30:2041-2048, 2010.
92. Wang S, Li W, Xue Z, et al: Molecular imaging of p53 signal pathway in lung cancer cell cycle arrest induced by cisplatin. Mol Carcinog: Jun. 5, 2012 (Epub ahead of print). doi: 10.1002/mc.21930.
93. Leon-Galicia I, Diaz-Chavez J, Garcia-Villa E, et al: Resveratrol induces downregulation of DNA repair genes in MCF-7 human breast cancer cells. Eur J Cancer Prev 22:11-20, 2013.
94. Han W, Pan H, Chen Y, et al: EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells. PLoS One 6:e18691, 2011.
95. Liu LZ, Zhou XD, Qian G, Shi X, Fang J and Jiang BH: AKT1 amplification regulates cisplatin resistance in human lung cancer cells through the mammalian target of rapamycin/p70S6K1 pathway. Cancer Res 67:6325-6332, 2007.
96. Chung AS, Kowanetz M, Wu X, et al: Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. J Pathol 227:404-416, 2012.
97. Waldner MJ and Neurath MF: Targeting the VEGF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:5-13, 2012.
98. Ishdorj G, Li L and Gibson SB: Regulation of autophagy in hematological malignancies: role of reactive oxygen species. Leuk Lymphoma 53:26-33, 2012.
99. Liu L, Yang M, Kang R, et al: DAMP-mediated autophagy contributes to drug resistance. Autophagy 7:112-114, 2011.
100. Fisher C, Coleman T and Plant N: Probabilistic orthology analysis of the ATP-binding cassette transporters: implications for the development of multiple drug resistance phenotype. Drug Metab Dispos 40:1397-1402, 2012.
101. Shukla S, Chen ZS and Ambudkar SV: Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance. Drug Resist Updat 15:70-80, 2012.
102. Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol 205:275-292, 2005.
103. Johnson SW, Ozols RF and Hamilton TC: Mechanisms of drug resistance in ovarian cancer. Cancer 71:644-649, 1993.
104. Sharan R, Ulitsky I and Shamir R: Network-based prediction of protein function. Mol Syst Biol 3:88, 2007.
105. Behm-Ansmant I, Rehwinkel J and Izaurralde E: MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol 71:523-530, 2006.
106. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116:281-297, 2004.
107. Kloosterman WP and Plasterk RH: The diverse functions of microRNAs in animal development and disease. Dev Cell 11:441-450, 2006.
108. Croce CM and Calin GA: miRNAs, cancer, and stem cell division. Cell 122:6-7, 2005.
109. Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D and Calin GA: miRNAs and their potential for use against cancer and other diseases. Future Oncol 3:521-537, 2007.